Jay Venkatesan, M.D.

Jay Venkatesan, M.D.

DirectoratElicio Therapeutics· In proxies 2022–2025

Pay in FY2023+60% from the year before · Elicio Therapeutics stock +2.8% the same year

Jay Venkatesan, M.D. was paid $2.4M in FY2023 (Dec), up 60%. Elicio Therapeutics stock rose 2.8% that year.

Pay$100 in the stock at the end of FY21 → $29
Pay is from the Summary Compensation Table of each Elicio Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Elicio TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role -93%
  2. Serina Therapeutics, Inc.Public company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  3. Zylem Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Cell Biotherapies, Inc.Public company · 11 yr
    • Director2015 – Present · 11 yrNo stock prices for these years
  5. Brookside CapitalPublic company
    • Director? – PresentNo stock prices for these years
  6. Iovance Biotherapeutics Inc.Public company · 5 yr
    • Director2013 – 2018 · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?